| Business Summary | | Sanguine
Corporation
is
engaged
in
developing
artificial
blood
to
be
used
by
the
medical
profession.
The
development
of
its
synthetic
red
blood
cell
product
called
"PHER-O2"
presently
comprises
its
sole
business
operations.
PHER-O2
is
composed
of
perfluoro-decalin
molecules,
or
synthetic
red
blood
cells,
purified
water
and
a
proprietary,
synthetic,
fluorinated
surfactant,
or
wetting
agent,
to
hold
the
emulsion
together.
Perfluoro-decalin
has
great
oxygen-carrying
capacity,
yet
it
can
be
as
much
as
900
times
smaller
than
a
red
blood
cell.
The
Company
believes
that
PHER-O2
can
carry
three
to
four
times
the
oxygen
of
human
blood
per
unit
volume.
This
increased
oxygen-carrying
capacity
would
make
PHER-O2
useful
in
the
treatment
of
heart
attacks,
strokes,
cancer
and
other
diseases
for
which
increased
oxygenation
is
beneficial. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Sanguine
Corporation,
a
development
stage
company,
is
engaged
in
the
development
of
a
synthetic
red
blood
cell
product
called
PHER-02,
a
second
generation
version
of
Fluosol,
the
only
FDA-approved
synthetic
blood
product
to
date.
For
the
six
months
ended
6/30/01,
the
Company
reported
no
revenue.
Net
loss
increased
less
than
1%
to
$443
thousand.
Higher
loss
reflects
increased
research
and
development
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Thomas Drees, Ph.D., 72 Chairman,
Pres, CEO | -- | Anthony Hargreaves, 73 Vice
Chairman, VP, Sec., Treasurer | $324K | David Nelson, 58 CFO | 100K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|